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Summary The incidence of cancer at sites other than the testis has been investigated in the families of 797
Norwegian and 178 Swedish patients diagnosed with testicular cancer during 1981-91. In the families of the
Norwegian patients, the total number of cancers in the relatives was significantly lower than the expected
number derived from national incidence rates [observed number of cancers 250, expected number of cancers
281.92, standardised incidence ratio (SIR) 0.89, 95% confidence interval (CI) 0.78-1.00]. This finding can be
accounted for almost entirely by the finding of fewer than expected prostate and gastrointestinal cancers in the
parents of cases. The other common cancers were found at slightly lower than or near the expected levels in the
relatives. In the Swedish cohort, which accounts for less than 20% of cases, the observed number of cancers
was very close to the expected number. Fourteen fathers of cases had prostate cancer compared with 27.57
prostate cancers expected, giving a SIR of0.51 (P=0.006). Mothers had more lung cancers (ten cases observed,
SIR =2.11, P=0.04) and cancers of the endometrium than expected (13 cases observed, SIR = 1.73, P=0.09).
These findings may be interpreted as support for theories proposing hormonal dysfunction as causing testicular
cancer. Fifty-four gastrointestinal cancers were observed in the parents compared with 68.48 expected
(SIR =0.78, P=0.082). Furthermore, testicular cancer was not found to be associated with the known
dominantly inherited cancer syndromes [Familial breast (-ovarian) cancer, hereditary non-polyposis colon
cancer]. However, one patient belonged to a Li-Fraumeni family, raising the possibility that testicular cancer
may be an infrequent component of this rare cancer syndrome. This study supports the hypothesis that families
of testicular cancer patients are not prone to cancer.
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Aggregation of diverse cancer types in one family may be
caused by shared genetic and/or environmental factors.
Mutations in disease genes or exposure to potent environ-
mental carcinogens may lead to malignant disease in a high
proportion of cases regardless of the presence of co-factors.
In other instances an interaction between an environmental
agent and a normal genetic variant is needed to result in
disease. This study was performed to examine possible
aggregation of diverse cancer types in the families of
testicular cancer patients.
Moss et al. (1985) and Swerdlow et al. (1987) have
reported an increase in breast cancer in mothers and lung
cancer in parents of testicular cancer patients respectively in
case-control studies. Similarly, there have been reports that
testicular cancer may be part of the Li-Fraumeni syndrome
(Hartley et al., 1989). However, these reports have not been
confirmed and it is still an open question whether or not
there are associated cancers in the families oftesticular cancer
patients or if testicular cancer is part of any of the known
cancer syndromes. Aetiological heterogeneity in testicular
cancer pathogenesis may exist and hence only a fraction of
the families of testicular cancer patients may show an
increase in associated cancers. The relatives of the patients
with familial and bilateral testicular cancer are of special
interest in this regard as these patients may be regarded as
the subgroups of testicular cancer patients most likely to have
the hypothetical 'testicular cancer gene(s)'.
There have been theories of hormonal imbalance in the
mothers ofpatients as a cause oftesticular cancer (Henderson
et al., 1979). Cancer of the endometrium has been related to
oestrogen excess (Olsson, 1990). Although not firmly
established, prostate cancer has similarly been linked to a
relative androgen excess and breast cancer to disturbances
both in the oestrogen and progesterone metabolism (Ross et
al., 1988; Olsson, 1990). Therefore, a finding of an altered
number of these hormone-related cancers in the families of
testicular cancer patients could be taken as support for
theories of hormone imbalances not only in the mothers of
cases but in both parents in testicular cancer families.
Materials and methods
Family data were collected using questionnaires sent to all
available patients treated at the Norwegian Radium Hospital,
Oslo, Norway and in Lund, Sweden from 1981 to 1991 as
described in the accompanying paper (Heimdal et al., 1996).
The two institutions are responsible for the post-orchiectomy
treatment of all testicular cancer patients in their catchment
areas and we believe we have complete ascertainment for the
time period in question as all incident cases in the population
are probands (Heimdal et al., 1990). All surviving patients
treated at the two institutions for 10.5 years that could be
located were invited to complete a questionnaire asking for
information on cancer in first-degree relatives and grand-
parents. The two institutions treated 1159 patients during this
time. A total of 1080 questionnaires were distributed. Of the
1080, 975 (90%) returned questionnaires with family
information. Cancers were classified according to the
International Classification of Diseases, 7th revision (ICD-7).
In Norway and Sweden reporting all malignant diseases to
National Cancer Registries has been mandatory since the
establishment of the registries in 1953 and 1958 respectively.
The National Cancer registries are incomplete for non-
melanoma skin cancers, which therefore were not analysed.
All cancers among relatives stated in the questionnaire were
checked against these registries. Inaccuracy in the cancer
localisation as recorded by the patients was corrected. For
the calculations, only cancers diagnosed after 1953 in Norway
and 1958 in Sweden were included. All calculations in this
report include only relatives with confirmed invasive cancers.
We were able to confirm 92% of the cancers reported by the
Norwegian patients in first-degree relatives and 84% in the
grandparents.
Standardised incidence ratios (SIRs) for first-degree
relatives were calculated as observed number/expected
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October 1995number for all cancers combined and for specific cancer
diagnoses (Table I) (Fossa et al., 1990, Heimdal et al., 1996).
Only first cancers occurring in the relatives were considered.
The calculation of SIRs for specific cancer diagnoses were
done in order to support or weaken previously published
hypotheses of testicular cancer pathogenesis as detailed in the
introduction. However, leukaemias were not tested because of
the suspicion that the Cancer Registry in Norway is
incomplete for these disease entities. Expected numbers of
cancers were derived according to cancer incidence in the
relevant Norwegian/Swedish population as described (Heim-
dal et al., 1996). The calculations were done separately on the
Norwegian and Swedish cohort before pooling the results.
Ninety-five per cent confidence intervals (CIs) were calculated
assuming a Poisson distribution of observed cases.
The Norwegian families were evaluated by one of the
authors (KH) for the occurrence of known familial cancer
syndromes according to previously published criteria (Moller
P., 1993; Li et al., 1988; Vasen et al., 1991). For these
families, both confirmed and reported cancers have been
included in the report.
Results
The first-degree relatives in the total material and of the
Norwegian testicular cancer patients had 10% fewer cancers
than expected (Table I). This finding is of borderline
statistical significance. In the relatives of the Swedish
patients, who account for less than 20% of all cases, SIR
was close to one. The SIR was lowest for fathers of cases.
For the children, numbers were too small to draw any
conclusions about non-testicular cancers.
When specific cancers were analysed in all cases a
statistically significant excess of lung cancers (ICD 162) in
mothers but not in other first-degree relatives was found
(Table II). The histology of the lung cancers in mothers was
small-cell carcinoma in three cases, squamous cell carcinoma
in two cases, adenocarcinoma in two cases, and carcinoid
tumour in one case. Histology was not known in the
remaining two cases. The excess of lung cases in mothers
prompted us to investigate the incidence of other smoking-
related cancers in mothers [ear-nose-throat tumours (ENT;
ICD 140- 148 and 160-161), oesophageal cancer (ICD 150),
and cancer of the urinary bladder (ICD 181)]. Only two ENT
tumours were observed and the SIR for other smoking-
related cancers in mothers was 0.41. Similarly, we found no
excess of these other smoking-related cancers in other first-
degree relatives (SIR=0.64).
Mothers, but not sisters, had a small excess of cancers of
the endometrium (Table II). Breast cancers were only slightly
increased in mothers and not elevated in sisters (Table II).
However, there was a statistically significant decrease in the
incidence of prostate cancers in the fathers (P=0.006).
Furthermore, fewer gastrointestinal cancers then expected
were observed both in mothers and fathers of cases, although
not statistically significant. The low SIR for gastrointestinal
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and prostate cancers in parents is responsible for most of the
deficit of cancers observed in the cohort when considering all
cancer diagnoses together.
There were increases, although they were not significant, in
the SIR for tumours of the nervous system in brothers and
sarcomas in fathers (Table II). One father with sarcoma was
counted twice because of double ascertainment of the family.
In one family a proband had both a brother and a son
with childhood rhabdomyosarcoma. The patient had a
combined tumour (malignant teratoma intermediate and
seminoma). The tumour had areas morphologically resem-
bling rhabdomyosarcoma. This family satisfies the criteria for
the Li-Fraumeni syndrome [one sarcoma before 45 years of
age; a first-degree relative with any cancer before that age;
and another close (first- or second-degree) relative with either
cancer before age 45 or sarcoma at any age; Li et al., 1988].
In addition, five families could be classified as familial breast
cancer according to previously published criteria (Moller P.,
1993). In one of these families, the proband was the son of an
unaffected mother and in two other families it was the father
of the proband who belonged to the breast cancer family.
Similarly, four families were classified as breast ovarian
cancer families. In these families one proband was the son
of an unaffected mother while the remaining probands were
sons of affected mothers. No family was compatible with the
hereditary non-polyposis colon cancer (HNPCC) syndrome.
In the Norwegian cohort, 77/797 (9.6%) of the patients
had bilateral and/or familial testicular cancer. We observed
22 non-testicular cancers in the first-degree relatives (sibs and
parents) and 28 in the grandparents of these patients. By
comparison, the first-degree relatives of the total Norwegian
cohort had 250 cancers and the grandparents 267 cancers.
Thus, 50/517 (9.7%) of the cancers in the relatives of the
Norwegian testicular cancer patients occurred in the families
of patients with bilateral and/or familial testicular cancer.
The observed number of cancers is too small to draw any
conclusions about specific types of cancer on clustering of
cases in certain families, and no obvious pattern emerged
(data not shown).
Discussion
In this study we found a decrease in total cancer incidence in
the families of testicular cancer patients. This apparent
decrease in incidence of major cancers may in part be
caused by underreporting by the probands and our method
ofverification ofcancers. We attempted to confirm the cancer
diagnosis in relatives reported to have had cancer, but did
not make attempts to check for cancer in those relatives
reported to be free ofthe disease. The fact that the SIRs were
even lower for grandparents than for first-degree relatives in
the Norwegian cohort (data not shown) support this
hypothesis of underreporting. Testicular cancer patients
may be less likely to know of cancers in the grandparents
than in their first-degree relatives. On the other hand, it may
be that there is a deficit of factors predisposing to common
Table I Standardised incidence ratios in relatives of testicular cancer patients for all non-testicular cancers combined
Number Person - Observed number Expected number
ofrelatives years of cancer cases of cancer cases SIR (95% CI)
Total patient
cohort
All first-degree 4967 145 614 294 326.56 0.90 (0.80-1.01)
relatives
Sons 661 10547 1 1.99 0.50 (0.01-2.80)
Daughters 600 9335 1 1.95 0.51 (0.01-2.85)
Brothers 993 32489 26 27.38 0.95 (0.63-1.4.1)
Sisters 917 30005 30 31.70 0.95 (0.65-1.36)
Fathers 889 28200 108 137.17 0.79 (0.65-0.95)
Mothers 907 31037 128 126.37 1.01 (0.85-1.21)
*Statistically significant at the 5% level.Cancer In relatives of testicular cancer patients
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Table II Standardised incidence ratios for selected cancers in relatives of testicular cancer patients
Observed Expected
Localisation ICD-7 Relative number of cancers number of cancers SIR (95% CI)
Gastro - 150-159 Brother 6 6.35 0.94 (0.35-2.06)
intestinal
Sister 2 4.45 0.45 (0.05-1.62)
Father 33 40.05 0.82 (0.57-1.17)
Mother 21 28.43 0.74 (0.47-1.14)
Total 62 79.28 0.78 (0.60-1.01)
Lung 162 Brother 3 3.27 0.92 (0.190 2.68)
Sister 1 1.02 0.98 (0.03-5.46)
Father 16 17.86 0.90 (0.52-1.48)
Mother 10 4.73 2.11 (1.01 -3.89)a
Total 30 26.88 1.11 (0.76-1.61)
Breast 170 Sister 9 7.89 1.14 (0.52-2.14)
Mother 35 31.89 1.10 (0.77-1.54)
Total 44 39.28 1.12 (0.82-1.50)
Endometrium 172 Sister 1 1.54 0.65 (0.02-3.62)
Mother 13 7.53 1.73 (0.92-2.95)
Total 14 9.07 1.54 (0.84-2.59)
Prostate 177 Brother 2 2.53 0.79 (0.10-2.86)
Father 12 25.04 0.48 (0.25 -0.84)a
Total 14 27.57 0.51 (0.28-0.83)a
Ovary 183 Sister 1 2.29 0.44 (0.01-2.40)
Mother 9 8.78 1.03 (0.47-1.92)
Total 10 11.07 0.90 (0.43-1.66)
Nervous 193 Brother 4 1.59 2.52 (0.69-6.41)
Sister 1 1.09 0.92 (0.02-5.11)
Father 5 3.19 1.57 (0.51-3.61)
Mother 2 2.48 0.81 (0.10-2.90)
Total 12 8.35 1.44 (0.74-2.50)
Sarcoma 196-197 Brother 2 1.07 1.87 (0.22-6.70)
Sister 1b 0.99 1.01 (0.03-5.60)
Father 4 1.92 2.08 (0.57-5.20)
Mother 1 2.16 0.46 (0.02-2.50)
Total 8 6.14 1.30 (0.56-2.50)
aStatisticaly significant at the 5% level. bOne father with sarcoma doubly ascertained.
cancers in the families of testicular cancer patients. Increasing
cancer incidence with age is usually explained by an
accumulation of carcinogenic factors over time. For
testicular cancer, factors operating very early in the life of
the individual (in utero or in early childhood) may be of
importance (Moller H, 1993). Therefore, if the low SIR for
major cancers combined was biologically important, it is
suspected that some confounding factor(s) would be
responsible for the effect. These would be genetic and/or
environmental risk factors that both predisposed to testicular
cancer and were protective for common cancers.
Also, there was no excess of cancers other than testicular
cancers in the relatives of familial and bilateral testicular
cancer cases. Only one family classified as possibly showing a
dominant cancer family syndrome had more than one
testicular cancer case (affected cousins related through the
proband's mother and her brother). This family may be
regarded as a possible familial breast cancer family on the
basis of two maternal aunts who had breast cancer at ages 48
and 56. The family is not included in the count of five breast
cancer families because our operational criterion of two first-
degree relatives affected before the age of 55 was not met
(Moller P, 1993). Furthermore, the mother of the proband is
unaffected at the age of 71 years.
The finding of altered SIRs for some of the hormonally
related cancers in parents may be taken as support for the
hypothesis that testicular cancer in part may be caused by
hormonal disturbances in both parents. Furthermore, it raises
the possibility that this hormonal derangement is inherited.
Our findings of an increase in endometrial but not breast
cancers in mothers and a decrease in prostate cancers in the
fathers support the idea that testicular cancer may in part be
caused by derangements in oestrogen/androgen-related
pathways not involving the progesterone systems. Our
finding of no increase in breast cancers is in contrast to
those of Moss et al. (1986). However, the latter authors
found an increase in breast cancers only in the mothers of
non-seminoma cases, and no other studies are available.
Endometrial cancers are sometimes part of the HNPCC
syndrome. None of the other component cancers of this
syndrome showed increased incidence in the relatives, and
none of the testicular cancer patients belonged to HNPCC
families that convincingly fulfilled the diagnostic criteria
published (Vasen et al., 1991).
- Patients cured of testicular cancer contract an excess of a
variety of other neoplasms including cancers of the lung and
gastrointestinal cancers, leukaemia and sarcomas (Kaldor et
al., 1987; Fossa et al., 1990; Moller H. et al., 1993; Jacobsen
et al., 1993; van-Leeuwen et al., 1993). These second
malignancies may share aetiological factors with testicular
cancer and/or be related to the treatment given for the
testicular cancer. Testicular cancer treatment is widely
believed to be the main cause of the second cancer. Family
data may be used to distinguish the two hypotheses since
cancers sharing aetiology with testicular cancer, in contrast to
cancers caused by the treatment for testicular cancer, wouldCancer in relatives of testicular cancer patients
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be expected to be increased in the relatives of testicular
cancer patients. For the common cancers, such as the
gastrointestinal and lung cancers (in males), the present
family data support the view that second cancers in testicular
cancer patients are treatment-related as both are found at
expected or lower than expected values in the relatives.
The finding of an increased SIR for lung cancers in
mothers is based on very few cases, one of which was a
malignant carcinoid tumour and may be due to chance.
Furthermore, there was no indication of an excess of other
smoking-related cancers in the mothers. Swerdlow et al.
(1987) noted an increase in lung cancers both in mothers and
in fathers of testicular cancer patients. The increase was,
however, not statistically significant. There are reports of an
increase in lung cancers in patients treated for testicular
cancer (Fossa et al., 1990; Moller H et al., 1993). This
increase is believed to be caused by the type of treatment
given for the testicular cancer.
We found four families with breast ovarian and five with
familial breast cancer in 978 families. However, two probands
were sons of probable non-carriers of the deleterious gene
(unaffected mothers) and two are difficult to evaluate because
the cluster of relatives that defined the family to be a familial
breast cancer family was in the paternal lineage. Thus, only
five testicular cancer patients are sons of probable gene
carriers. It is difficult to calculate the expected number of
such families in this sample since the estimates of the gene
frequency for the rare dominant genes involved in breast and
ovarian cancer vary (Newman et al., 1988; Claus et al., 1991;
Iselius et al., 1991, 1992). If we set the gene frequency to
1:200-1:300, the expected number of breast(-ovarian)
families would be 3-5. Thus, on the basis of the present
data, testicular cancer is not shown to be a clear component
of this syndrome, although this possibility cannot be
excluded.
One patient belonged to a Li-Fraumeni cancer family.
Including the present case testicular germ cell tumours have
now been reported in four and ovarian germ cell tumour in
one Li-Fraumeni family (Hartley et al., 1989; Scott et al.,
1993). This raises the possibility that in rare cases gonadal
germ cell tumours are part of this extremely rare cancer
family syndrome. Molecular data from testicular germ cell
tumours, however, do not seem to support this view since
very few tumours have been shown to have TP53 mutations
(Heimdal et al., 1993; Peng et al., 1993; Ye et al., 1993;
Strohmeyer et al., 1993).
In conclusion, there is no overall excess of cancer in
relatives of testicular cancer patients, but some interesting
imbalances in the incidence of some cancer types possibly
related to hormonal imbalances in the parents of testicular
cancer patients were observed. Neither sporadic unilateral
nor familial and bilateral testicular cancer seem to be an
obvious part of any of the known cancer family syndromes.
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